Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants
about
The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral DrugsAntiretroviral drug regimens to prevent mother-to-child transmission of HIV: a review of scientific, program, and policy advances for sub-Saharan AfricaPregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trialHead circumferences of children born to HIV-infected and HIV-uninfected mothers in Zimbabwe during the preantiretroviral therapy eraProtocol for a drugs exposure pregnancy registry for implementation in resource-limited settings.Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infantsPre-exposure prophylaxis for HIV prevention in women: current perspectivesPreventing and managing HIV infection in infants, children, and adolescents in the United States.HIV-exposed infants: rethinking care for a lifelong condition.Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.Tenofovir rescue therapy in pregnant females with chronic hepatitis BPregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trialLower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis.Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected ChildrenPotential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in femalesAntiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.In Utero Exposure to Antiretroviral Drugs: Effect on Birth Weight and Growth Among HIV-exposed Uninfected Children in BrazilMaternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.Development and validation of the first liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of multiple antiretrovirals in meconium.Growth and body composition of uninfected children exposed to human immunodeficiency virus: comparison with a contemporary cohort and United States National StandardsAtazanavir exposure in utero and neurodevelopment in infants: a comparative safety study.Bone health in HIV-infected children and adolescents.In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.PrEP as Peri-conception HIV Prevention for Women and Men.What is needed to eliminate new pediatric HIV infections: the contribution of model-based analyses.A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy.Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?Chronic hepatitis B virus infection and pregnancy.Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence.Adverse drug reactions associated with antiretroviral therapy during pregnancy."I did not want to give birth to a child who has HIV": Experiences using PrEP during pregnancy among HIV-uninfected Kenyan women in HIV-serodiscordant couples.Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approachSafety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
P2860
Q26744617-E4CC8548-B15E-483F-901E-18973A41F0AEQ27014960-9788EC53-DA5E-454F-B363-94591F2CFB8FQ28483723-331964C5-8ED0-4C97-A480-383F6CED7A55Q30381646-67F6E0A4-CC4C-4C28-B205-CEC8780446B2Q30528461-39F0B9A8-D519-4B3F-A869-5FF15190841DQ33747993-BB43962B-1B4F-4B76-9232-2927BCFCF7E7Q33766562-B20785B3-7EB8-4580-9F8B-FB6A1C2EDB55Q33808736-8C5AF91F-29B8-4388-8C04-548713B768F4Q33871174-185F08BB-85B3-4DDF-8BBE-EF91FB80622DQ34371989-C9C5D376-E7B2-418F-B4EA-000ED2E54EE3Q35128259-D1FEFE8D-8BE0-4FD6-A2BC-E867D66F4D31Q35184560-422E5A0B-1A32-42A9-80B2-675A6AA98EC1Q35659264-015E195F-745A-4147-AF32-83C10959DD15Q35703796-CA8B2B05-AA62-491E-9CDC-45AF869A7AAEQ35840548-C4F99EF4-2B45-455F-A663-0F11DD488D16Q36070335-B5F38545-7C2E-45CC-BF47-4E2D70F68697Q36173112-AB711F68-70C2-4D93-B4B5-32169C1F978CQ36438846-524312D8-A4A9-4E46-88BB-58F4AA84586AQ36443769-0762E3DE-891D-479F-A81D-00435460AA53Q36448494-EB389AA5-559F-4413-9E9E-21B3EA0C7F56Q36586078-3D4928BC-2C81-47BF-A334-B81019F5C9D8Q36800100-B3DCA667-32B4-42D4-AB34-B5FBA8D1BE28Q36809068-36AA484C-3920-4B08-80C4-CE6B47C06508Q36853210-E7530E02-DB67-4384-BEEE-2ACE213736EFQ36882631-97DDCE8D-15E3-49CE-80A9-FD133504CA7EQ36948111-BC1DDCB1-5FA4-4378-870D-B599AF0122FEQ36963511-EC6AE903-20DD-49D8-9027-94FE91B9F1E6Q37238095-FA746646-9B6D-4FBC-ACF2-5BDDFC187F10Q37277571-43F0B88F-85A6-44EA-BD99-478A4FA762BDQ37283062-CE18FEE1-1225-4710-B722-EBFE52E901C9Q37298218-B37B3BAC-EBD3-449F-A2BF-B148764070A6Q37342120-89E69722-706C-4F4F-B897-F793F2198769Q37613468-334CD148-18CA-470F-9C34-29C92857D825Q38174178-93D14D85-A71A-42FC-B0C4-07A49FB97368Q38217668-C66FFF4C-ACC4-4D73-B39B-4496CDDAF907Q38260025-05F7F36C-4C90-486D-9975-8373753049D4Q38267557-842A1860-80DC-49F8-B818-6C448BA689E8Q38641080-BFFE3E00-A632-45E0-9477-B47B04E1D48FQ38737364-5D0376D1-C514-427E-AB0F-929BD671907BQ38750453-C589D1F9-03E8-4B9A-A149-DD6D8302BFCD
P2860
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Safety of tenofovir use during ...... HIV-exposed uninfected infants
@ast
Safety of tenofovir use during ...... HIV-exposed uninfected infants
@en
type
label
Safety of tenofovir use during ...... HIV-exposed uninfected infants
@ast
Safety of tenofovir use during ...... HIV-exposed uninfected infants
@en
prefLabel
Safety of tenofovir use during ...... HIV-exposed uninfected infants
@ast
Safety of tenofovir use during ...... HIV-exposed uninfected infants
@en
P2093
P2860
P1433
P1476
Safety of tenofovir use during ...... HIV-exposed uninfected infants
@en
P2093
D Heather Watts
Deborah Kacanek
Denise L Jacobson
George K Siberry
George R Seage
Hermann Mendez
Katherine Tassiopoulos
Kenneth C Rich
Paige L Williams
Pediatric HIV/AIDS Cohort Study (PHACS)
P2860
P304
P356
10.1097/QAD.0B013E328352D135
P407
P577
2012-06-01T00:00:00Z